rpl-7 Antibody

What is RPL7 and what is its biological significance?

RPL7 (ribosomal protein L7) is a component of the 60S ribosomal subunit with a molecular weight of approximately 29-30 kDa. It plays crucial roles in protein translation and rRNA processing. The human version contains 248 amino acids and is widely expressed across multiple tissue types. RPL7 is localized primarily in the cytoplasm and belongs to the Universal ribosomal protein uL30 family . Its biological significance extends beyond structural roles in ribosomes, as altered expression has been associated with various diseases including cancer and developmental disorders .

What are the validated applications for RPL7 antibodies?

RPL7 antibodies have been validated for multiple research applications including:

These applications have been verified across human, mouse, and rat samples . It is recommended to titrate antibodies in each experimental system to obtain optimal results.

What controls should be included when using RPL7 antibodies?

When using RPL7 antibodies, researchers should include several controls:

• Positive controls: Use HEK-293 cells or mouse kidney tissue for Western blot, which have been confirmed to express detectable levels of RPL7

• Negative controls: Include samples where RPL7 is knocked down or tissues known not to express the protein

• Antibody controls: Run a secondary antibody-only control to assess non-specific binding

• Isotype controls: Include a non-specific IgG from the same species as the primary antibody

These controls help establish specificity and validate experimental findings.

What are the optimal sample preparation methods for different RPL7 antibody applications?

For Western blot analysis, cells or tissues should be lysed in a buffer containing protease inhibitors. For immunohistochemistry, the recommended antigen retrieval method uses TE buffer at pH 9.0, though citrate buffer at pH 6.0 can serve as an alternative . For immunofluorescence, fixation with 4% paraformaldehyde followed by permeabilization with 0.1-0.5% Triton X-100 typically yields good results. For immunoprecipitation, gentle lysis conditions are recommended to preserve protein-protein interactions.

How should RPL7 antibodies be stored and handled to maintain reactivity?

RPL7 antibodies should be stored at -20°C where they remain stable for approximately one year after shipment. The typical storage buffer contains PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . For smaller preparations (20μl) containing 0.1% BSA, aliquoting is generally unnecessary. Repeated freeze-thaw cycles should be avoided to preserve antibody activity. When handling the antibody, maintain sterile conditions and avoid contamination.

What troubleshooting strategies can address common issues with RPL7 antibody experiments?

When troubleshooting RPL7 antibody experiments, consider:

• For weak Western blot signal: Increase antibody concentration, extend incubation time, or enhance detection methods

• For high background: Optimize blocking conditions, increase washing steps, or reduce primary/secondary antibody concentrations

• For multiple bands: Verify with positive controls, as RPL7 may show slight variations in molecular weight (29-30 kDa) due to post-translational modifications

• For inconsistent IHC staining: Optimize antigen retrieval methods, as RPL7 detection may require specific pH conditions

How can RPL7 antibodies be used to investigate ribosome biogenesis pathways?

Researchers can employ RPL7 antibodies to investigate ribosome biogenesis through several advanced approaches:

• Subcellular fractionation combined with Western blotting to track RPL7 distribution between nucleolar, nucleoplasmic, and cytoplasmic compartments

• Immunofluorescence co-localization studies with nucleolar markers to monitor pre-ribosomal particle formation

• Pulse-chase experiments with immunoprecipitation to measure incorporation rates into mature ribosomes

• RNA immunoprecipitation assays to identify rRNA precursors associated with RPL7 during assembly

These approaches provide insights into altered ribosome assembly pathways that may occur in disease states.

What is the significance of anti-RPL7/L12 antibody levels in colorectal cancer research?

Studies have revealed a temporal association between anti-RPL7/L12 antibody levels and colorectal cancer progression. Interestingly, both polyp patients and early-stage (I/II) colorectal cancer patients show significantly elevated anti-RPL7/L12 titers compared to healthy individuals (p=0.013) . In contrast, advanced-stage cancer patients (stages III/IV) do not exhibit this elevation. Age-adjusted odds ratios for colorectal tumors associated with above-median RPL7/L12 titers ranged from 0.7 for late-stage tumors to 4.04 for polyps .

This pattern suggests anti-RPL7/L12 antibodies may serve as potential early biomarkers for colorectal cancer development. The increased immune response appears to be specific to this bacterial antigen rather than a general phenomenon caused by loss of colonic barrier function, as indicated by the absence of increased antibody production to endotoxin .

How do RPL7 expression patterns differ between normal and pathological tissues?

RPL7 expression patterns show tissue-specific variations in both normal and pathological conditions. While RPL7 is widely expressed across multiple tissues, its expression levels may be altered in pathological states. In cancer research, RPL7 has been detected in human skin cancer tissue through immunohistochemistry .

When analyzing expression patterns, researchers should consider:

What factors influence the specificity of RPL7 antibodies?

Several factors can influence RPL7 antibody specificity:

• The immunogen used for antibody production - RPL7 fusion protein Ag6104 is used in some validated antibodies

• The purification method - antigen affinity purification enhances specificity

• The host species and antibody class - rabbit polyclonal antibodies are commonly used

• The targeted epitope region - N-terminal vs. C-terminal targeting may affect recognition of splice variants or modified forms

• Cross-reactivity with structurally similar ribosomal proteins

Researchers should verify antibody specificity through multiple validation methods, including Western blot with positive and negative controls, and when possible, confirmation with mass spectrometry.

How can researchers quantitatively analyze RPL7 expression levels?

For quantitative analysis of RPL7 expression, researchers can employ:

• Quantitative Western blot with appropriate loading controls and standard curves

• ELISA assays for measuring RPL7 levels in biological samples

• Quantitative immunofluorescence with digital image analysis

• Mass spectrometry-based approaches for absolute quantification

When performing quantitative analysis, normalization to appropriate housekeeping proteins or total protein content is essential. For the most accurate results, multiple technical and biological replicates should be included.

What considerations are important when multiplexing RPL7 antibodies with other markers?

When multiplexing RPL7 antibodies with other markers, researchers should consider:

• Antibody compatibility - select antibodies from different host species to avoid cross-reactivity

• Fluorophore selection - choose fluorophores with minimal spectral overlap

• Sequential staining protocols - may be necessary for closely related targets

• Optimization of individual antibodies before multiplexing

• Inclusion of single-stain controls for accurate signal interpretation

Proper optimization of multiplexed assays ensures accurate co-localization studies and prevents false interpretation of protein interactions.

How are RPL7 antibodies being utilized to study extraribosomal functions?

Beyond their canonical role in ribosome structure and function, ribosomal proteins like RPL7 have emerging extraribosomal functions. Researchers are employing RPL7 antibodies to investigate these functions through:

• Co-immunoprecipitation coupled with mass spectrometry to identify non-ribosomal interaction partners

• Chromatin immunoprecipitation to detect potential DNA-binding activities

• Subcellular fractionation to track non-ribosomal pools of RPL7

• Proximity ligation assays to visualize and quantify interactions with non-ribosomal proteins

These approaches help distinguish canonical ribosomal functions from roles in processes such as cell cycle regulation, stress response, or transcriptional control.

What methodological approaches can detect post-translational modifications of RPL7?

Post-translational modifications of RPL7 can be detected through:

• Phospho-specific antibodies targeting known modification sites

• Mass spectrometry-based proteomics to identify and quantify modifications

• 2D gel electrophoresis to separate differently modified forms

• Mobility shift assays to detect changes in electrophoretic mobility

• Enzyme treatment (phosphatases, deubiquitinases) followed by Western blotting to confirm modification types

Understanding these modifications provides insights into regulatory mechanisms affecting RPL7 function beyond its structural role in ribosomes.

How do genetic variations impact RPL7 antibody recognition and experimental outcomes?

Genetic variations in RPL7 may impact antibody recognition in several ways:

• Polymorphisms or mutations within epitope regions can directly affect antibody binding

• Splice variants may alter protein structure or remove epitope regions entirely

• Species-specific variations may affect cross-reactivity in comparative studies

Researchers should be aware of these potential variations when designing experiments across different experimental models or when studying populations with known genetic diversity. Validating antibody reactivity with samples of known genetic background is recommended for critical applications.